What's Happening?
Ollin Biosciences has announced a successful $330 million Series B financing round to support the global Phase 3 development of OLN324, a VEGF/Ang2 bispecific antibody aimed at treating diabetic macular edema (DME) and wet age-related macular degeneration
(wAMD). The financing was co-led by TCGX and ARCH Venture Partners, with participation from several healthcare-focused investors. OLN324 has shown promising results in a head-to-head clinical study against faricimab, demonstrating faster and greater improvements in retinal anatomy and vision gains. The company plans to initiate Phase 3 trials in the second half of 2026. Additionally, Ollin is advancing OLN102, a bispecific antibody for thyroid eye disease and Graves’ disease, into clinical development.
Why It's Important?
The development of OLN324 represents a significant advancement in the treatment of retinal vascular diseases, which are major causes of vision loss. The $15 billion retina market stands to benefit from a new standard of care that OLN324 could provide, potentially offering improved outcomes for patients. The successful financing round underscores investor confidence in Ollin's scientific approach and the commercial potential of its therapies. This development could lead to enhanced treatment options for patients suffering from DME and wAMD, addressing unmet medical needs in ophthalmology.
What's Next?
Ollin Biosciences plans to begin global Phase 3 trials for OLN324 in the latter half of 2026, following positive feedback from the FDA and EMA. The company aims to maximize the clinical and commercial potential of OLN324, positioning itself for further growth. The advancement of OLN102 into clinical development also suggests a broader pipeline strategy targeting autoimmune conditions. Stakeholders, including investors and healthcare providers, will be closely monitoring the outcomes of these trials and their implications for future treatment standards.
